宫颈癌预后蛋白质组学特征的识别与验证
研究在TCGA-155和MCW-61两个宫颈浸润癌队列中验证TCGA基于RPPA的蛋白质组聚类预后分层,并基于随机生存森林与Cox模型筛选的22个生存相关抗体构建风险评分算法,将患者分为低、中、高风险生存组,在两个独立队列中均能预测生存结局。
要点
- 在TCGA-155和MCW-61两个宫颈浸润癌队列中验证了TCGA蛋白质组聚类(激素、EMT、PI3K/AKT)的预后分层能力。
- 基于22个生存相关抗体构建的算法可将宫颈浸润癌患者分为低、中、高风险生存组。
- 该22抗体特征在两个独立宫颈浸润癌患者组中均能预测生存结局。
核心结论
- 研究提供包含22个抗体的特征,在两个独立的宫颈浸润癌患者组中准确预测了生存结局。
- 作者认为,未来需要在更多宫颈浸润癌队列中研究这些候选生物标志物,以充分确定其临床潜力。
研究设计与样本
- 研究纳入两个宫颈浸润癌患者队列,均附有RPPA数据和临床病理资料:TCGA来源的155例样本(TCGA-155)和另外61例独立样本(MCW-61)。
- 使用173个共有RPPA抗体的数据,在两个宫颈浸润癌队列中重复进行Silhouette聚类分析。
- 通过随机生存森林(RSF)和Cox比例风险回归模型识别生存相关抗体(SAA),并据此计算每例患者的指数评分。
- 采用Kaplan-Meier生存分析和log-rank检验评估并比较聚类或风险组的生存结局。
主要发现
- 研究验证了TCGA报告的蛋白质组聚类(激素、EMT、PI3K/AKT)的预后分层能力。
- 基于22个生存相关抗体构建的算法将宫颈浸润癌女性分为低、中、高风险生存组。
- 该22抗体特征在两个独立的宫颈浸润癌患者组中均准确预测了生存结局。
关键数值与推荐
- 使用173个共有RPPA抗体进行Silhouette聚类分析。
- 基于22个生存相关抗体计算每例患者的指数评分,并据此分为低、中、高风险生存组。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出,需要在更多宫颈浸润癌队列中研究这些候选生物标志物,才能充分确定其临床潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To date, The Cancer Genome Atlas (TCGA) has provided the most extensive molecular characterization of invasive cervical cancer (ICC). Analysis of reverse phase protein array (RPPA) data from TCGA samples showed that cervical cancers could be stratified into 3 clusters exhibiting significant differences in survival outcome: hormone, EMT, and PI3K/AKT. The goals of the current study were to: 1) validate the TCGA RPPA results in an independent cohort of ICC patients and 2) to develop and validate an algorithm encompassing a small antibody set for clinical utility. METHODS: Subjects consisted of 2 ICC patient cohorts with accompanying RPPA and clinical-pathologic data: 155 samples from TCGA (TCGA-155) and 61 additional, unique samples (MCW-61). Using data from 173 common RPPA antibodies, we replicated Silhouette clustering analysis in both ICC cohorts. Further, an index score for each patient was calculated from the survival-associated antibodies (SAAs) identified using Random survival forests (RSF) and the Cox proportional hazard regression model. Kaplan-Meier survival analysis and the log-rank test were performed to assess and compare cluster or risk group survival outcome. RESULTS: In addition to validating the prognostic ability of the proteomic clusters reported by TCGA, we developed an algorithm based on 22 unique antibodies (SAAs) that stratified women with ICC into low-, medium-, or high-risk survival groups. CONCLUSIONS: We provide a signature of 22 antibodies which accurately predicted survival outcome in 2 separate groups of ICC patients. Future studies examining these candidate biomarkers in additional ICC cohorts is warranted to fully determine their clinical potential.
引用
- Rader JS, Pan A, Corbin B, et al. Identification and validation of a prognostic proteomic signature for cervical cancer. Gynecol Oncol. 2019. PMID: 31477280. doi:10.1016/j.ygyno.2019.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。